Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.46 |
| ▸ | TSHR | P16473 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | CD44 | P16070 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 4/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.40 |
| ▸ | RECQL | P46063 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.40 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31532309 | 0.82 | CD44 (0.44) | HSD17B10TSHRHPGDTHRBMAPK1 | |
| SCHEMBL2527588 | 0.82 | CD44 (0.44) | HSD17B10TSHRHPGDTHRBMAPK1 | |
| SCHEMBL10614584 | 0.82 | GAA (0.46) | HSD17B10TSHRHPGDTHRBMAPK1 | |
| Hydrochloric Acid SCHEMBL3843541 | 0.80 | ALDH1A1 (0.44) | HSD17B10TSHRHPGDTHRBMAPK1 | |
| SCHEMBL10771021 | 0.78 | HSD17B10 (0.59) | HSD17B10TSHRHPGDTHRBMAPK1 | |
| SCHEMBL9251854 | 0.78 | CD44 (0.50) | HSD17B10TSHRHPGDMAPK1CD44 | |
| SCHEMBL736999 | 0.76 | HSD17B10 (0.50) | HSD17B10TSHRHPGDTHRBMAPK1 | |
| SCHEMBL10976016 | 0.76 | CD44 (0.48) | TSHRMAPK1CD44GAAALDH1A1 | |
| SCHEMBL9755707 | 0.73 | HSD17B10 (0.46) | HSD17B10TSHRHPGDTHRBMAPK1 | |
| SCHEMBL30807892 | 0.73 | HSD17B10 (0.46) | HSD17B10TSHRHPGDTHRBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036699-A | THR-beta modulators and methods of use thereof | 阿利戈斯治疗公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-112805005-B | Thyroxine receptor beta agonist compounds | 拓臻股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-3840755-B1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | TERNS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250304561-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250236615-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | Terns, Inc. | 2025-07-24 | — | — | US | disclosed |
| EP-4523692-A2 | MODULATORS OF THR-SS AND METHODS OF USE THEREOF | Aligos Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-3965884-B1 | MODULATORS OF THR-BETA WITH A DIOXO-1,2,4-TRIAZYL HEAD GROUP | ALIGOS THERAPEUTICS INC (US) | 2025-01-15 | — | — | EP | disclosed |
| US-12180192-B2 | Modulators of THR-β and methods of use thereof | ALIGOS THERAPEUTICS, INC. (US) | 2024-12-31 | — | — | US | disclosed |
| US-20220348561-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | TERNS PHARMACEUTICALS INC (US) | 2022-11-03 | — | — | US | disclosed |
| EP-3965884-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | Aligos Therapeutics, Inc. (US) | 2022-03-16 | — | — | EP | disclosed |
| US-20200115362-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | TERNS PHARMACEUTICALS, INC. (KY) | 2020-04-16 | — | — | US | disclosed |
| US-20200115362-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | TERNS PHARMACEUTICALS, INC. (KY) | 2020-04-16 | — | — | US | disclosed |
| US-20200062742-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | Terns, Inc. | 2020-02-27 | — | — | US | disclosed |
| US-20200062742-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | Terns, Inc. | 2020-02-27 | — | — | US | disclosed |
| WO-2020041741-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | Terns, Inc. (US) | 2020-02-27 | — | — | WO | disclosed |
| US-7109164-B2 | Aniline-derived ligands for the thyroid receptor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1257526-B1 | ANILINE-DERIVED LIGANDS FOR THE THYROID RECEPTOR | BRISTOL MYERS SQUIBB CO (US) | 2005-05-11 | — | — | EP | disclosed |
| US-20050032890-A1 | Aniline-derived ligands for the thyroid receptor | KARO BIO AB (SE) | 2005-02-10 | — | — | US | disclosed |
| US-6800605-B1 | WITH A HYPOLIPIDEMIC AGENT, AN ANTIDIABETIC AGENT, AN ANTIDEPRESSANT, A BONE RESORPTION INHIBITOR, AN APPETITE SUPPRESSANT AND/OR AN ANTI-OBESITY AGENT | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-05 | — | — | US | disclosed |
| US-4752547-A | RECORDING LAYER CONTAINS REDUCING AGENT, LEWIS BASE COMPLEX, AND REDUCIBLE DYE FORMING COMPOUND | EASTMAN KODAK COMPANY (US) | 1988-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062742-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | THRB, THRA, TSHR | HSD17B10 1504/4885TSHR 3/4885HPGD 3088/4885 |
| US-20250304561-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | THRB, THRA, TRHR | HSD17B10 1479/4885TSHR 4/4885HPGD 1247/4885 |
| US-20220348561-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | THRB, THRA, TSHR | HSD17B10 1586/4885TSHR 3/4885HPGD 3065/4885 |
| US-20200115362-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | THRB, THRA, TSHR | HSD17B10 1586/4885TSHR 3/4885HPGD 3065/4885 |
| US-20050032890-A1 | Aniline-derived ligands for the thyroid receptor | TSHR, THRB, THRA | HSD17B10 454/4885TSHR 1/4885HPGD 1810/4885 |
| US-20250236615-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | THRB, THRA, TSHR | HSD17B10 1504/4885TSHR 3/4885HPGD 3088/4885 |
| US-12180192-B2 | Modulators of THR-β and methods of use thereof | THRB, THRA, TRHR | HSD17B10 1506/4885TSHR 4/4885HPGD 1390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.